3 Discussion
ECMO is commonly used in pediatric patients with CHD, particularly in
the setting of low-output failure, arrhythmia, cardiopulmonary arrest,
or inability to transition from CPB [5].However, despite significant advances in ECMO techniques and management
over the last several years, prognosis remains poor[6]. The underlying causes of death vary from
cardiovascular events to organ failure, including GI, renal, neurologic,
coagulation, and it carries a significant cost burden[7]. Neonates are special population, who’s
cardiomyocytes are softer with less contractile tissue and lower energy
reserves. Longer CPB time leads to poor myocardial cell compliance and
insensitivity to drugs, and these lead to heart failure controlled by
drugs difficultly after open-heart surgery. According to the latest
statistics from ELSO 2017, the neonatal survival rate of CHD is 47% and
discharge rate is 39% [8]. In our study, although
the survival rate of neonate is as high as 52.17%, there are many risk
factors that affect the outcomes.